Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
Project Number5R01CA265975-03
Former Number1R01CA265975-01
Contact PI/Project LeaderSIDRANSKY, DAVID Other PIs
Awardee OrganizationJOHNS HOPKINS UNIVERSITY
Description
Abstract Text
Abstract
Survival studies show marked racial disparity effect in head and neck cancer between African Americans (AA)
and whites. AA may present with more advanced disease and have twice the age-adjusted mortality rate
compared with whites. Immune checkpoint inhibitors offer new hope for some patients with recurrent or
metastatic disease, but further improvement in therapy is contingent upon developing a comprehensive
immunogenetic map of neoplastic evolution in HNSCC. Nearly 20% of patients with oral cancers harbor multiple
pre-malignant lesions showing signs of dysplasia, often visually identified as leukoplakia. As some of these
lesions evolve to malignant neoplasms, they represent intermediate steps in HPV negative oral squamous cell
carcinoma (OSCC) progression. Genetic changes arising at the earliest stages of tumor development drive tumor
progression and curtail the propensity of the immune system to destroy precancerous cells. Genetic aberrations
selected during OSCC evolution can create a dysfunctional tumor immune microenvironment by upregulating
key immunomodulatory ligands that induce immune tolerance and T cell exhaustion. The role of cross-talk
between neoplastic cells and their immune microenvironment, particularly in its early developmental stages, has
yet to be elucidated. Moreover, little baseline information exists in these lesions in AA, and even less is known
about the key genetic changes that lead to progression and immune invasion in this population. The central
premise of this project is that key racial differences in both inherited and somatic genetic changes during the
progression of OSCC impact the expression of key immunomodulatory cytokines or ligands within the tumor
microenvironment in order to escape an antitumor immune response. The specific aims of this project will use
whole-exome sequencing, RNA sequencing, high-throughput computational analyses, and tissue cell
localization methods to map the specific mutational patterns and corresponding immune landscape represented
by expression of key immunomodulatory ligands and signatures of immune tolerance and T cell exhaustion in
lesions along the pathway of oral tumorigenesis. This data will help us understand the biologic underpinnings of
the different progression pathways and interactions with the immune microenvironment. Such mapping should
provide crucial insights that have significant implications for risk assessment, tumor surveillance and treatment
interventions for OSCC in AA patients.
Public Health Relevance Statement
Survival studies show marked racial disparity effect in head and neck cancer between African Americans and
Non-Latinx Whites (Whites). This project explores how key racial differences in genetic changes during the
progression of HNSCC impact the expression of key immunomodulatory cytokines or ligands within the tumor
microenvironment in order to escape an antitumor immune response. This molecular mapping will provide crucial
insights that have significant implications for risk assessment, tumor surveillance and treatment interventions for
oral cancer tumors in African American patients.
No Sub Projects information available for 5R01CA265975-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA265975-03
Patents
No Patents information available for 5R01CA265975-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA265975-03
Clinical Studies
No Clinical Studies information available for 5R01CA265975-03
News and More
Related News Releases
No news release information available for 5R01CA265975-03
History
No Historical information available for 5R01CA265975-03
Similar Projects
No Similar Projects information available for 5R01CA265975-03